Poster
Measurement and Evaluation
Katie Lucero, PhD, MS
Vice President, Audience Engagement, Analytics, Outcomes & Insights
Medscape, LLC
Linda A. Battiato, MSN, RN
Director, Medical Education Grants
Eli Lilly
Since early 2022, Eli Lilly has supported a curriculum in Alzheimer’s disease (AD) to increase assessment of cognition, earlier diagnosis of AD, and awareness of clinical trial data. The initiative is now wrapping up year 2. Several online accredited activities were offered in 2022, starting with a self-assessment, followed by a suite of
Matched questions were asked pre- and post-point of learning in years 1 and 2, and real world documented clinical information (claims) in year 2 were leveraged to assess outcomes and additional learning needs.
We used our understanding of the process of behavior change (Transtheoretical Mode) to inform our outcomes analysis. [Prochaska 1983; Prochaska 1992] Ultimately, we needed learners to learn new information but also reinforce knowledge and skills to move toward clinical practice change. We are able to show through outcomes data consistent increases in knowledge, skills, and confidence, which signals we were meeting learning needs. We also conducted research leveraging the underlying data to further understand how different outcomes may be related which then informed our educational strategy and helped further understand the behavior change process using outcomes commonly measured in CME.
The session will share our case study from both the supporter and medical education company perspective so that others may become aware of how one may think longitudinally about education design and think about evaluation as more than solely outcomes. In addition, experience will be shared to convey how we leveraged outcomes to communicate success to the supporter and the supporter internally to their stakeholders.
Unlock Your Potential :
This session will allow you to learn about the process of behavior change through CME and to understand from industry supporter and medical education company perspectives how to use data to inform and drive multi-year initiatives that have the goal of changing the diagnosis and treatment landscape of a chronic condition.